CADScor System is now being utilized by Leading Cardiology Practice in the New York Capital Region

Acarix, a leader in advanced acoustic-based cardiac diagnostics, announces the integration of the CADScor System at Capital Cardiology Associates' newest location in Niskayuna, New York. Capital Cardiology Associates is the leading cardiology practice treating cardiovascular disease in the Albany, New York metropolitan area, with a cardiac care team comprised of over 35 board-certified cardiologists, 35+ advanced care providers, and more than 300 healthcare professionals.

The CADScor System is a point-of-care diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze the patient's coronary blood flow. The system calculates a patient-specific CAD-score and couples it with risk factors to rapidly indicate the patient’s risk of significant coronary stenosis for immediate risk stratification before potential secondary evaluation.

"We are pleased to announce the integration of the CADScor System within Capital Cardiology Associates' new facility,” stated Acarix President & CEO Aamir Mahmood. “Capital Cardiology Associates' concept of providing quick and easy access to care for patients, coupled with cutting-edge technology to improve the lives of the community and beyond, aligns perfectly with the benefits of the CADScor System. This synergy presents an invaluable opportunity to help physicians make evaluation decisions while removing unnecessary patient anxiety with immediate results at point of care.”

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 29,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit www.acarix.com